The Effect of Preoperative Biliary Drainage with or without Pancreatic Stenting on Complications after Pancreatoduodenectomy: A Retrospective Cohort Study

Jiangtao Chu,1 Shun He,1 Yan Ke,1 Xudong Liu,1 Peng Wang,2 Wei Zhang,2 Guotong Qiu1,2 Chengfeng Wang,2 Jianwei Zhang2, and Guiqi Wang1

1The Department of Endoscopy, National Cancer Center/National clinical research center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
2The Department of Pancreatic and Gastric Surgery, National Cancer Center/National clinical research center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Correspondence should be addressed to Jianwei Zhang; panchutong@163.com and Guiqi Wang; wangguiq@126.com

Received 23 February 2021; Revised 10 April 2021; Accepted 16 April 2021; Published 30 April 2021

1. Introduction

Biliary obstruction is a common problem in patients undergoing pancreaticoduodenectomy (PD). However, the necessity for preoperative biliary drainage (PBD) remains controversial [1]. A recent well-published study suggests that routine PBD is not recommended because it is associated with increased complications when PD is conducted [2]. However, if the bilirubin is markedly elevated in the symptomatic patient, or surgery needs to be delayed to optimize medical comorbidities or to
manage neoadjuvant therapy, PBD is still required [1]. Trans-papillary endoscopic biliary drainage (EBD) with endoscopic retrograde cholangiopancreatography (ERCP) is recognized as the gold standard procedure for malignant biliary obstruction (MBO) prior to PD [3].

However, the ERCP procedure can cause complications such as pancreatitis, cholangitis, bleeding, and perforation, which delays the subsequent pancreaticoduodenectomy, and may cause postoperative complication [4].

Postoperative pancreatitis is a common complication after ERCP, especially for patients with difficult cannulation. Many studies have reported that pancreatic duct stenting can reduce the occurrence of pancreatitis after ERCP [5]. A cost-effective analysis showed that restricting preventive pancreatic stenting to high-risk patients is the most cost-effective strategy [6]. The European Society of Gastrointestinal Endoscopy strongly recommends that patients at high risk of postoperative pancreatitis, such as inadvertent guidewire insertion, opacification of the pancreatic duct, double-guidewire cannulation, could select pancreatic stenting [7].

Therefore, the correlation between pancreatic duct stenting and its resultant complications after pancreaticoduodenectomy needs to be evaluated. The purpose of our study was to analyze and assess the effect of pancreatic duct stenting on the complication of pancreaticoduodenectomy. This study compared the complication incidence of pancreaticoduodenectomy in patients with PBD and plastic pancreatic duct stenting (PS group) and patients with PBD alone (NPS group).

2. Methods

2.1. Patients Selection. From March 2015 to July 2019, the data of patients who underwent successful PD after biliary drainage with or without pancreatic stenting were extracted from the National Cancer Center database, and a retrospective observational cohort study was conducted. This study was approved by the institutional review board and ethics committee. Patients enrolled in the study met all the following requirements: (1) age ≥ 18 years old, (2) with low malignant biliary obstruction, (3) successful PBD, or with/without pancreatic duct stenting, and (4) successful pancreaticoduodenectomy. Those who have undergone short-circuit surgery, percutaneous biliary drainage, or intraoperative tumor metastasis or unable to undergo radical resection were excluded.

A total of 83 patients who underwent successful PD after biliary drainage were identified. 31 patients had periampullary carcinoma, 16 had a tumor located in the head of the pancreas, 22 had cholangiocarcinoma, and 14 had duodenal adenocarcinomas, respectively. Among the 83 who had successful PD, 29 patients underwent biliary drainage and pancreatic duct stenting (PS group), and 54 patients underwent only biliary drainage without pancreatic duct stenting (NPS group).

2.2. Biliary Drainage and Pancreaticoduodenectomy. PBD procedure was performed with nasobiliary drainage, metal stent, or plastic stenting. When the double-guidewire method was selected for difficult bile duct cannulation or the guidewire was accidentally inserted into the pancreatic duct, a 5-Fr plastic pancreatic duct stent with flanks on the inside was routinely implanted.

The standard surgical procedure for resectable tumors was the pylorus-preserving pancreaticoduodenectomy, including removal of all lymph nodes on the right side of the portal vein and mesenteric artery [8]. If metastasis into the proximal duodenum or pylorus was suspected, a classic Whipple procedure was performed, with resection of the distal stomach. If limited metastasis into the portal or superior mesentric vein was found, a wedge resection of these vessels was included in the procedure [8, 9]. No specific modifications of the surgical technique were expected for patients with jaundice, particularly with respect to creating the hepaticojejunostomy.

2.3. Data Collection and Definition. Demographic characteristics of the included patients were evaluated, including pancreaticoduodenectomy, operation time, intraoperative blood transfusion, perioperative complications, clinical pathological results, margin conditions, and other indicators. The length of hospital stay was defined from the day of surgery to the day of discharge.

The severity of perioperative complications (i.e., perioperative bleeding, abdominal infection, delayed gastric emptying, bile anastomotic leakage, and pancreatic anastomotic leakage) was divided into 5 grades as described in Table 1 [10, 11]. Grade 1-2 was defined as the mild complication, and grade 3 or higher was defined as the severe complication.

2.4. Primary Outcome. The main outcome measure is the incidence of complications after pancreaticoduodenectomy of the enrolled patients.

2.5. Secondary Outcome. The secondary outcome included hospital stay time, operative time, and intraoperative blood transfusion volume.

2.6. Statistical Analysis. Continuous variables were described by median and range, while categorical variables were described by frequency and percentage. To analyze the differences between the two groups (pancreatic duct stent group and nonpancreatic duct stent group), categorical variables were analyzed using Fisher’s exact test, and continuous variables were tested using ANOVA. The length of hospital stay and intraoperative blood transfusion was transformed into a normal distribution through logarithmic transformation, and ANOVA test was performed. R language was used to analyze the risk factors of surgical complications in univariate and multivariate analysis. Factors with a P value of <0.20 in univariate analysis were included in the multivariate analysis. Patients with missing values were excluded from the analysis.

3. Results

Between the two groups (Table 2), there have been no statistically significant differences in all demographic data including hospital stay time, operative time, and intraoperative blood transfusion volume, except the tumor location.

The overall complication rate of the study was 68.7%, including perioperative complications, severity of (grade 3 or higher) complications, delayed gastric emptying, biliary
Table 1: Complication criteria.

| Grade definition | Description |
|------------------|-------------|
| 0                | no complications |
| 1                | Oral medications or supportive care |
| 2                | IV medical therapy with resolution or antibiotics or specialized nutritional support |
| 3                | interventional radiology, endoscopic, or operative intervention |
| 4                | chronic deficit or disability associated with sequelae of this event |
| 5                | death associated with sequelae of this event |

anastomotic leakage, pancreatic anastomotic leakage, abdominal infection, and wound infection as listed in Table 3. No significant differences were found between the two groups in overall complications. While postoperative gastrointestinal dysfunction rates differed with delayed gastric emptying occurring in 3 (5.56%) in the NPS group, compared to 6 (20.7%) in the PS group (NPS vs. PS $P = 0.06$).

In the univariate regression model analysis about postoperative gastrointestinal dysfunction, pancreatic duct stenting was correlated with higher rates of gastrointestinal dysfunction [odds ratio (OR) = 4.25, $P = 0.0472$. In the multivariate regression model, PS had more delayed gastric emptying complication than the NPS group when adjusting for age. Table 4 shows that no other covariate was found significantly associated with the complications.

4. Discussion

The necessity of preoperative biliary drainage (PBD) prior to pancreaticoduodenectomy (PD) remained unclear because some studies showed that PBD procedure may be related to the complications of PD [4, 10, 12–16]. However, the PBD would be the recommended bridge management to resolve jaundice in some situations, such as acute cholangitis, obstruction with bilirubin levels exceeding 250 μmol/L, severe pruritus, jaundice associated with renal failure or comorbidities, or need of neoadjuvant chemotherapy for borderline resectable lesions [3]. Meanwhile, ERCP procedure with biliary stent or nasobiliary tube for PBD was preferred because of higher safety and better oncological outcomes [17, 18].

Postoperative pancreatitis was the most common complication of ERCP. According to reports, the incidence of postoperative pancreatitis was 2-10% for all patients, 2-4% for low-risk groups, and 8-40% for high-risk groups [19]. Pancreatic duct stent implantation was recommended to prevent postoperative pancreatitis [20], especially when the guidewire was accidentally inserted into the pancreatic duct, or the double-guidewire method was adopted.

There were few studies to evaluate the influence of pancreatic duct stenting during PD on the complications of pancreaticoduodenectomy. A retrospective study by John et al. in 2018 showed that simultaneous cholangiopancreatic duct drainage increased the incidence of postoperative pancreatic leakage [21]. This study enrolled only 5 cases of simultaneous cholangiopancreatic duct drainage, which was regarded as a rare event during data analysis and Firth logistic regression. An opposite result was presented in our study, showing no significant difference between the two groups regarding the incidence of postoperative pancreatic leakage or bile duct leakage. The different results may be contributed to the method of pancreaticojejunal anastomosis and the proficiency of pancreatic duct stenting.

When analyzing each postoperative complication separately, there has been no statistical difference in terms of operation time, hospital stay, intraoperative blood transfusion, postoperative bleeding, pancreatic leakage, bile leakage, wound infection, abdominal infection, and organ dysfunction between the two groups. However, the incidence of delayed gastric emptying in the pancreatic duct stenting group was higher than that in the NPS group ($P = 0.06$). The multivariate and univariate adjusted analysis showed that pancreatic duct stenting was an independent risk factor for delayed gastric emptying (OR = 4.25, $P = 0.0472$), which was considered as one of the most common complications after pancreatic surgery, with about 19%-57% incidence [22].

The potential mechanisms for delayed gastric emptying after PD have been unclear. Some studies have reported that other postoperative complications, such as pancreatic leakage, accumulation of peripancreatic fluid, or abdominal abscess, could increase the incidence of gastric emptying disorders [23]. However, many patients develop delayed gastric emptying in the absence of pancreatic leakage or other abdominal infections, which may represent a distinct pathology [24]. The study is the first to report that the PBD and pancreatic duct stenting prior to pancreaticoduodenectomy would increase the risk of postoperative delayed gastric emptying. The potential pancreatic inflammation after pancreatic duct stenting may play an important role in delayed gastric emptying. To most patients, although delayed gastric emptying was generally not life-threatening, patients could suffer abdominal discomfort, longer hospitalization time, increased hospitalization costs, and reduction of postoperative life quality.

The results suggest a hard choice in the PBD procedure when considering post-ERCP pancreatitis and outcomes of pancreaticoduodenectomy. Therefore, a PBD procedure without influence on the pancreatic duct would be preferred, such as endoscopic ultrasonography- (EUS-) guided biliary drainage method which can avoid contacting the pancreatic bile duct segmental in accessing the bile duct [25].

Several limitations in our study cannot be neglected. First, pancreaticoduodenectomy was not performed by the same surgeon. The difference in surgery proficiency may be one uncertainty, which affected the incidence of postoperative delayed gastric emptying. Second, our study did not find a significant difference in the incidence of other complications between the two groups, which may be attributed to the small number of cases of preoperative simultaneous cholangiopancreatic duct drainage. We cannot exactly exclude the possibility that pancreatic duct stent implantation may increase the incidence of other complications, such as surgical wound infection and abdominal infection. Also, the increase of the incidence of delayed gastric emptying needs to be clarified by a multicenter study.
### Table 2: Demographic and clinical characteristics of patients NPS group and PS group.

|                          | [ALL] N = 83 | NPS* N = 54 | PS* N = 29 | P value  |
|--------------------------|-------------|-------------|------------|----------|
| Sex (female)             |             |             |            | 0.193    |
| Age                      | 58.0 [51.5; 63.0] | 57.0 [51.0; 62.8] | 59.0 [53.0; 63.0] | 0.436    |
| #BMI                     |             |             |            | 0.684    |
| Fat                      | 35 (42.2%)  | 24 (44.4%)  | 11 (37.9%) |          |
| Low                      | 4 (4.82%)   | 2 (3.70%)   | 2 (6.90%)  |          |
| Normal                   | 44 (53.0%)  | 28 (51.9%)  | 16 (55.2%) |          |
| Biliary drainage         |             |             |            | 1.000    |
| ENBD                     | 66 (79.5%)  | 43 (79.6%)  | 23 (79.3%) |          |
| Metal biliary stent      | 1 (1.20%)   | 1 (1.85%)   | 0 (0.00%)  |          |
| Plastic bile duct stent  | 16 (19.3%)  | 10 (18.5%)  | 6 (20.7%)  |          |
| Tumor location           |             |             |            | 0.024    |
| Ampulla                  | 31 (37.3%)  | 26 (48.1%)  | 5 (17.2%)  |          |
| Bile duct                | 22 (26.5%)  | 12 (22.2%)  | 10 (34.5%) |          |
| Duodenum                 | 14 (16.9%)  | 9 (16.7%)   | 5 (17.2%)  |          |
| Pancreas                 | 16 (19.3%)  | 7 (13.0%)   | 9 (31.0%)  |          |
| Stay time                | 18.0 [14.0; 22.5] | 20.0 [14.0; 23.0] | 17.0 [15.0; 22.0] | 0.681    |
| Blood transfusion        | 300 [0.00; 750] | 0.00 [0.00; 675] | 500 [0.00; 800] | 0.070    |
| Operation duration       | 366 [306; 454] | 359 [314; 466] | 369 [300; 432] | 0.909    |

### Table 3: Outcomes of patients' PS group and NPS group.

|                          | [all] N = 83 | NPS* N = 54 | PS* N = 29 | P value  |
|--------------------------|-------------|-------------|------------|----------|
| Complication criteria    |             |             |            | 0.57     |
| None                     | 26 (31.3%)  | 15 (27.8%)  | 11 (37.9%) |          |
| Mild                     | 42 (50.6%)  | 28 (51.9%)  | 14 (48.3%) |          |
| Severe                   | 15 (18.1%)  | 11 (20.4%)  | 4 (13.8%)  |          |
| Bile anastomotic leakage | 7 (8.43%)   | 4 (7.41%)   | 3 (10.3%)  | 0.691    |
| Bleeding                 |             |             |            | 0.846    |
| Blood transfusion        | 11 (13.3%)  | 8 (14.8%)   | 3 (10.3%)  |          |
| Dead                     | 2 (2.41%)   | 2 (3.70%)   | 0 (0.00%)  |          |
| Hemostasis               | 3 (3.61%)   | 2 (3.70%)   | 1 (3.45%)  |          |
| None                     | 67 (80.7%)  | 42 (77.8%)  | 25 (86.2%) |          |
| Abdominal infection      |             |             |            | 0.670    |
| Interventional therapy   | 10 (12.0%)  | 8 (14.8%)   | 2 (6.90%)  |          |
| Medication               | 24 (28.9%)  | 15 (27.8%)  | 9 (31.0%)  |          |
| None                     | 49 (59.0%)  | 31 (57.4%)  | 18 (62.1%) |          |
| Surgical wound infection | 13 (15.7%)  | 8 (14.8%)   | 5 (17.2%)  | 0.761    |
| Gastrointestinal dysfunction | 9 (10.8%) | 3 (5.56%)   | 6 (20.7%)  | 0.060    |
| Organ dysfunction        | 6 (7.23%)   | 5 (9.26%)   | 1 (3.45%)  | 0.660    |
| Pancreatic anastomotic leakage |       |             |            | 0.380    |
| None                     | 58 (69.9%)  | 36 (66.7%)  | 22 (75.9%) |          |
| A                        | 8 (9.64%)   | 7 (13.0%)   | 1 (3.45%)  |          |
| B                        | 17 (20.5%)  | 11 (20.4%)  | 6 (20.7%)  |          |
5. Conclusion

This study has shown that preoperative biliary drainage and pancreatic duct stenting prior to pancreaticoduodenectomy would increase the risk of postoperative delayed gastric emptying, while with no significant difference to the overall incidence of postoperative complications. More studies, especially RCTs, are preferred to verify the results in the future study.

Data Availability

From March 2015 to July 2019, the data of patients who underwent successful PD after biliary drainage with or without pancreatic stenting were extracted from the National Cancer Center database.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] M. Costa Santos, C. Cunha, S. Velho et al., "Preoperative biliary drainage in patients performing pancreaticoduodenectomy: guidelines and real-life practice," Acta Gastro-Enterologica Belgica, vol. 82, no. 3, pp. 389–395, 2019.
[2] Y. Shaib, M. A. Rahal, M. O. Rammal, A. Mailhac, and H. Tamim, "Preoperative biliary drainage for malignant biliary obstruction: results from a national database," *Journal of Hepato-Biliary-Pancreatic Sciences*, vol. 24, no. 11, pp. 637–642, 2017.

[3] A. Zarzarvadjian le Bian, D. Fuks, R. Dalla Valle, M. Cesaretti, V. Violi, and R. Costi, "Effectiveness and risk of biliary drainage prior to pancreatoduodenectomy: review of current status," *Surgery Today*, vol. 48, no. 4, pp. 371–379, 2018.

[4] H. Moole, M. Bechtold, and S. R. Puli, "Efficacy of preoperative biliary drainage in malignant obstructive jaundice: a meta-analysis and systematic review," *World Journal of Surgical Oncology*, vol. 14, no. 1, p. 182, 2016.

[5] V. Phillip, A. Pukitis, A. Epstein et al., "Pancreatic stenting to prevent post-ERCP pancreatitis: a randomized multicenter trial," *Endoscopy International Open*, vol. 7, no. 7, pp. E860–E868, 2019.

[6] H. J. Hwang, M. A. Guidi, C. Curvale, J. Lasa, and R. Matano, "Post-ERCP pancreatitis: early precut or pancreatic duct stent? A multicenter, randomized-controlled trial and cost-effectiveness analysis," *Revista Española de Enfermedades Digestivas*, vol. 109, no. 3, pp. 174–179, 2017.

[7] J. M. Dumonceau, A. Andriulli, B. J. Elmunzer et al., "Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014," *Endoscopy*, vol. 46, no. 9, pp. 799–815, 2014.

[8] D. J. Gouma, E. J. M. Nieven van Dijkum, and H. Obertop, "The standard diagnostic work-up and surgical treatment of pancreatic head tumours," *European Journal of Surgical Oncology (EJSo)*, vol. 25, no. 2, pp. 113–123, 1999.

[9] R. C. van Geenen, F. J. ten Kate, L. T. de Wit, T. M. van Gulik, H. Obertop, and D. J. Gouma, "Segmental resection and wedge excision of the portal or superior mesenteric vein during pancreatoduodenectomy," *Surgery*, vol. 129, no. 2, pp. 158–163, 2001.

[10] C. Liu, J. W. Lu, Z. Q. du, X. M. Liu, Y. Lv, and X. F. Zhang, "Association of preoperative biliary drainage with postoperative morbidity after pancreatoduodenectomy," *Gastroenterology Research and Practice*, vol. 2015, Article ID 796893, 8 pages, 2015.

[11] A. Schaible, P. Schemmer, T. Hackert et al., "Location of a biliary leak after liver resection determines success of endoscopic treatment," *Surgical Endoscopy*, vol. 31, no. 4, pp. 1814–1820, 2017.

[12] S. P. Povoski, M. S. Karpeh Jr., K. C. Conlon, L. H. Blumgart, and M. F. Brennan, "Association of preoperative biliary drainage with postoperative outcome following pancreatoduodenectomy," *Annals of Surgery*, vol. 230, no. 2, pp. 131–142, 1999.

[13] T. A. Sohn, C. J. Yeo, J. L. Cameron, H. A. Pitt, and K. D. Lillemoe, "Do preoperative biliary stents increase postpancreatectoduodenectomy complications?" *Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract*, vol. 4, no. 3, pp. 258–268, 2000.

[14] P. W. Pisters, W. A. Hudec, K. R. Hess et al., "Effect of preoperative biliary decompression on pancreatoduodenectomy-associated morbidity in 300 consecutive patients," *Annals of Surgery*, vol. 234, no. 1, pp. 47–55, 2001.

[15] N. Arkadopoulos, M. A. Kyriazi, I. S. Papanikolaou et al., "Preoperative biliary drainage of severely jaundiced patients increases morbidity of pancreatoduodenectomy: results of a case-control study," *World Journal of Surgery*, vol. 38, no. 11, pp. 2967–2972, 2014.

[16] E. C. H. Lai, S. H. Y. Lau, and W. Y. Lau, "The current status of preoperative biliary drainage for patients who receive pancreatocoduodenectomy for periampullary carcinoma: a comprehensive review," *The Surgeon*, vol. 12, no. 5, pp. 290–296, 2014.

[17] Y. Murakami, K. Uemura, Y. Hashimoto et al., "Does preoperative biliary drainage compromise the long-term survival of patients with pancreatic head carcinoma?," *Journal of Surgical Oncology*, vol. 111, no. 3, pp. 270–276, 2015.

[18] K. Uemura, Y. Murakami, S. Satoi et al., "Impact of preoperative biliary drainage on long-term survival in resected pancreatic ductal adenocarcinoma: a multicenter observational study," *Annals of Surgical Oncology*, vol. 22, Supplement 3, pp. 1238–1246, 2015.

[19] G. Z. Li, F. Wang, J. Fang, H. L. Zha, and Q. Zhao, "Risk factors for post-endoscopic retrograde cholangiopancreatography pancreatitis: evidence from 1786 cases," *Medical Science Monitor*, vol. 24, pp. 8544–8552, 2018.

[20] M. L. Freeman, "Preventing post-ERCP pancreatitis: update 2016," *Current Treatment Options in Gastroenterology*, vol. 14, no. 3, pp. 340–347, 2016.

[21] J. M. Manipadam, S. Mahesh, J. M. Kadamapuzha, and H. Ramesh, "The effect of preoperative biliary and pancreatic drainage on postoperative pancreatic fistula: a retrospective cohort study," *The Surgery Journal*, vol. 4, no. 1, pp. e37–e42, 2018.

[22] M. N. Wente, S. V. Shrikhande, J. Klee et al., "Management of early hemorrhage from pancreatic anastomoses after pancreatectoduodenectomy," *Digestive Surgery*, vol. 23, no. 4, pp. 203–208, 2006.

[23] S. Ráty, J. Sand, E. Lantto, and I. Nordback, "Postoperative acute pancreatitis as a major determinant of postoperative delayed gastric emptying after pancreatectoduodenectomy," *Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract*, vol. 10, no. 8, pp. 1131–1139, 2006.

[24] R. J. Ellis, A. R. Gupta, D. B. Hewitt et al., "Risk factors for post-pancreatectoduodenectomy delayed gastric emptying in the absence of pancreatic fistula or intra-abdominal infection," *Journal of Surgical Oncology*, vol. 119, no. 7, pp. 925–931, 2019.

[25] F. I. Téllez-Ávila, M. A. Figueroa-Zacarías, E. Muñoz-Anaya et al., "EUS-guided biliary drainage in patients with distal malignant biliary obstruction requires fewer interventions and has a lower cost compared to ERCP biliary drainage," *Surgical Endoscopy*, 2020.